{
  "id": 20661406,
  "title": "Targeting Folate Receptor Reverses Colorectal Cancer’s Resistance to Immunotherapy in Mice",
  "url": "https://urgent.news/2026/11/18/targeting-folate-receptor-reverses-colorectal-cancers-resistance-to",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-11-18T21:16:04.000Z",
  "source": {
    "name": "GEN Biotechnology",
    "slug": "gen-biotechnology",
    "url": "https://www.genengnews.com/topics/cancer/targeting-folate-receptor-reverses-colorectal-cancers-resistance-to-immunotherapy-in-mice/"
  },
  "original_language": "en",
  "account": "Colorectal cancer (CRC) ranks third globally among cancer cases. Despite immune checkpoint blockade showing promise, only 15% of patients experience significant benefits from treatments such as anti-PD-1. A new study reveals that folate receptor sustains colorectal cancer's ability to resist immunotherapy. Targeting this receptor with a drug could restore the treatment's efficacy in mice, suggesting that integrating folate receptor-based treatments into existing regimens could improve outcomes for patients with treatment-resistant tumors. Published in Science Translational Medicine, the study titled \"Targeting cancer immune evasion with anti-FOLR1 antibody-drug conjugate potentiates anti-PD-1 efficacy in colorectal cancer\" finds that high expression of the folate receptor α (FOLR1) predicts poor immune checkpoint blockade (ICB) response, increased cancer stemness, and unfavorable patient outcomes. The research demonstrates that mirvetuximab soravtansine, an approved antibody-drug conjugate that inhibits FOLR1, restores anti-tumor immunity and re-sensitizes colorectal cancer tumors to anti-PD-1 blockade in mice.",
  "summary": "Targeting FOLR1 with an approved antibody-drug conjugate restored anti-tumor immunity and enhanced anti-PD-1 effectiveness in colorectal cancer, overcoming immune evasion in mouse models. The post Targeting Folate Receptor Reverses Colorectal Cancer’s Resistance to Immunotherapy in Mice appeared first on GEN - Genetic Engineering and Biotechnology News .",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}